Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Immutep Limited logo — The global leader in developing LAG-3 therapeutics (ASX: IMM...

Immutep Limited

The global leader in developing LAG-3 therapeutics (ASX: IMM, NASDAQ: IMMP)

Founded 1987 Australia Australia 49 employees Post-IPO Equity Total: $108.65M Biotechnology, Health Care +1

General Information

Company Name Immutep Limited
Founded Year 1987
Location Australia Australia
Employees 49
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Immutep Limited. To contact Immutep Limited, visit immutep.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Immutep Limited compare?

A PDF of Immutep Limited and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Immutep Limited soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Immutep Limited

**Immutep Limited** is a late-stage clinical biotechnology company that specializes in developing novel LAG-3 immunotherapies to combat cancer and autoimmune diseases. The company's innovative approach involves leveraging the unique capabilities of Lymphocyte Activation Gene-3 (LAG-3) to modulate the immune response. Their product portfolio includes eftilagimod alpha, a proprietary soluble LAG-3 protein, and MHC Class II agonist in oncology, as well as IMP761, the world's first LAG-3 agonist targeting the root causes of autoimmune diseases. Founded in **1987** and based in **Australia**, Immutep trades on the Australian Securities Exchange (ASX: IMM) and the NASDAQ (IMMP). The company continues to attract investments, with the most recent being a post-IPO equity investment on **2nd June 2023**. Immutep's dedication to delivering innovative treatment options to patients and maximizing value for shareholders makes it an attractive prospect for investors seeking opportunities in the **biotechnology**, **healthcare**, and **pharmaceutical** industries. With its cutting-edge approach to harnessing the potential of LAG-3, Immutep stands out as a global leader in developing therapeutics targeting key medical challenges.

Business keywords: immunotherapy, oncology, clinical trials, autoimmune diseases, cancer therapeutics, immunostimulatory factor, therapeutic antibody, immune response modulation, immune control mechanism, LAG-3 agonist, MHC Class II agonist, ASX listed company, NASDAQ listed company

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $89.60M -
05 Jun 2024
Post IPO Equity Undisclosed -
02 Jun 2023
Grant $2.20M -
06 Sep 2022
Post IPO Equity $10.00M 3
Altium Capital Platinum Asset Management
Altium Capital, Platinum Asset Management +1
09 Jul 2019
Post IPO Equity $6.85M -
12 Mar 2018

Immutep Limited Alternatives & Competitors

View All Alternatives
Immutep Limited vs
Tolerx, Inc.
Tolerx, Inc. United States

Tolerx, Inc., a world leader in immunology, has a portfolio of innovative, first-in-class drug candi...

Venture round
9 employees
Biotechnology, Health Care
Compare Immutep Limited vs Tolerx, Inc.
Immutep Limited vs
ImCheck Therapeutics
ImCheck Therapeutics France

Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic

Grant
57 employees
Biopharma, Biotechnology
Compare Immutep Limited vs ImCheck Therapeutics
Immutep Limited vs
Apexigen
Apexigen United States

Creating Transformative Immunotherapies for Patients with Cancer

Post-IPO Equity
11 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Immutep Limited

The global leader in developing LAG-3 therapeutics (ASX: IMM, NASDAQ: IMMP)
Immutep Limited was founded in 1987.
Immutep Limited is headquartered in Australia.
Immutep Limited operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on immunotherapy, oncology, clinical trials and autoimmune diseases.
Immutep Limited has approximately 49 employees.
Immutep Limited has completed 5 funding rounds, raising a total of $108.65M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Immutep Limited include Tolerx, Inc., ImCheck Therapeutics, Apexigen, OSE Immunotherapeutics, Simcha Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Immutep Limited and Tolerx, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Immutep Limited, https://bouncewatch.com/company/immutep-limited, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout